ALL refractory to glucocorticoids presented with high expression levels of the anti-apoptotic BCL2 family protein MCL1, due to a hyper activation of the PI3K/AKT/mTOR network (Wei et al., 2006), and specific MCL1 inhibitors are currently under evaluation for anti-leukemia activity (Ramsey et al., 2018). Here, BCL2 is linked to leukemia.